



CANCER BIOPARTNERING & INVESTMENT FORUM Focusing on Advances in Immuno-Oncology

March 2017

New York Academy of Sciences

USA

07:30 **Registration & Coffee**

08:30 Welcome Speech by Leonard Sachs, Managing Director, Sachs Associates

Chaired by:

Mike Rice, Principal, Defined Health, a Cello Health business

Panelists:

Denis Patrick, Executive Director, Head External R&D Innovation, Oncology Research Unit, Pfizer, Inc.

Pharma-Biotech DealMaking in IO: "Understanding the Current Needs and Choices" Panel

Loic Vincent, Sr. Director Immunology Partnerships, Takeda Pharmaceuticals International GmbH

Niels Emmerich, Global Head Search & Evaluation Oncology, AbbVie, Inc.

Sarah Solomon, Partner, Goodwin Procter LLP

William Kuziel, Director, External Scientific Affairs, Daiichi Sankyo, Inc.

09:40

10:50

08:40

Keynote Speech: "Gene Editing Coupled to Cell Therapy, a Paradigm Shift in Oncology" by André Choulika, Chairman and CEO, Cellectis

10:00

Coffee Break

10:15

Keynote Speech: "Drug Chess - Planning a Few Moves Ahead of the Competition" by Peter Kolchinsky, Portfolio Manager and Managing Director, RA Capital Management

10:35 **Follow on Q&A Session**

Development Strategies for Early and Late Stage 10 Combination Therapies Panel

Paul Rennert, President & CSO, Aleta Biotherapeutics

James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center

Panelists:

Andrew Hopkins, CEO, Exscientia Ltd.

Carlos de Sousa, Chief Executive Officer, Immunicum AB

Jonathan Pachter, Chief Scientific Officer, Verastem, Inc.

Mark Breidenbach, Research Analyst, Roth Capital Partners, LLC

PR Companies Track B

Moderated by:

Sherry Grisewood, Dawson James Securities, Inc.

Western Oncolytics Ltd. 11:40

11:50 RXi Pharmaceuticals, Corp. - [NASDAQ: RXII]

12:00 **Immunicum AB - [IMMU:SS]**

Inovio Pharmaceuticals, Inc. - [NASDAQ: INO] 12:20

12:40 Verastem, Inc. - [NASDAQ: VSTM] **PR Companies Track A** Moderated by:

Brad Loncar, Loncar Investments, LLC

10:35 TapImmune, Inc. - [NASDAQ:TPIV]

10:55 UbiVac

11:55

11:15 Cue Biopharma, Inc.

11:35 Adaptimmune Therapeutics - [NASDAQ:ADAP]

Onconova Therapeutics, Inc. - [NASDAQ:ONTX]

12:15 PCI Biotech AS - [PCIB:OL]

12:35 Prima BioMed - [ASX:PRR]

13:00 **Networking Lunch**

13:00 **Networking Lunch Cancer Vaccines: Immuno-Priming & Tumor Antigens Panel PR Companies Track C** Moderated by: Co-Chaired by: Robert Wotczak, Wotczak Group James Mulé, Associate Center Director for Translational Research, Moffitt Cancer Center Paul Rennert, President & CSO, Aleta Biotherapeutics Panelists: 14:00 ImmunoMet Therapeutics, Inc. 14:00 Andrew Allen, President and CEO, Gritstone Oncology, Inc. Arthur Kuan, Managing Partner, Perseverance Capital Bernard Fox, CEO, UbiVac 14:10 Amphivena Therapeutics, Inc. Glynn Wilson, CEO, Taplmmune, Inc. Kurt Rote, CEO, Western Oncolytics Ltd. Exscientia Ltd. 14:20 **Cell & Gene Therapies - Advances and Setbacks Panel** Co-Chaired by: Biren Amin, Managing Director, Jefferies, LLC Gregory Frost, Managing Director, F1BioVentures 14:40 Solasia Pharma K.K. - [TYO: 4597] Panelists: 14:45 André Choulika, Chairman and CEO, Cellectis Helen Tayton-Martin, Chief Business Officer, Adaptimmune Therapeutics Ramesh Kumar, President and CEO, Onconova Therapeutics, Inc. 15:00 Genprex, Inc. Stefanos Theoharis, SVP, Corporate Development & Partnering, Cell Medica 15:20 Fostering Innovation Through Collaboration with AMC's and Foundations Panel **Gem Pharmaceuticals, LLC** Co-Chaired by: Howard Fingert, Senior Medical Director for Clinical Intelligence, Takeda Pharmaceuticals 15:30 **Oncovita** International GmbH Kuldeep Neote, Senior Director, New Ventures, Johnson & Johnson Innovation Center-Boston 15:30 Panelists: Ferran Prat, Vice President, Strategic Industry Ventures, MD Anderson Cancer Center Gary Sclar, Vice President, Dana-Farber Innovations, Dana-Farber Cancer Institute Lee Greenberger, SVP, Leukemia & Lymphoma Society Louise Perkins, CSO, Melanoma Research Alliance 16:20 **Coffee Break Public Markets & Investor Roundtable** Co-Chaired by: Bibhash Mukhopadhyay, Principal, New Enterprise Associates Steve Dickman, Chief Executive Officer, CBT Advisors Panelists: 16:55 Brad Loncar, Portfolio Manager, Loncar Investment, LLC Joseph Sum, Director of Research, EcoR1 Capital, LLC Rahul Jasuja, Senior Vice President, Senior Biotechnology Analyst, FBR & Co. Stuart Barich, Managing Director, Raymond James Financial, Inc. 17:40 **Networking Reception** 18:40 End of the 5th CBPI Forum



















